Bridging Chasms in Bladder Cancer Care: An Expert Case-based Review of Treatment Selection and Sequencing in an Era of Therapeutic Novelty

This educational session will comprehensively evaluate the current state of the bladder cancer management paradigm and investigate the emergence of new data across the totality of the disease continuum, with a particular emphasis on evidence-based treatment sequencing and the role of antibody-drug conjugates (ADCs) in subsequent lines of therapy for advanced disease. To conclude the session, activity attendees will get to apply the therapeutic principles they’ve learned to real-world clinical scenarios which will focus on patient-centric treatment selection and sequencing, as well as recognition, mitigation, and management of treatment-related adverse events.

• 1.50 AMA PRA Category 1 Credit™
• 1.50 Participation

Collect credit: https://www.ceconcepts.com/gu-cancer23-podcast